Request Deal Involvement

Sanofi completed the acquisition of Inhibrx for $1.7bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Skadden Arps Slate Meagher & Flom

legal advisors to financial advisors

Skadden Arps Slate Meagher & Flom

Paul Weiss Rifkind Wharton & Garrison

legal advisors

Paul Weiss Rifkind Wharton & Garrison

Centerview Partners

financial advisors

Centerview Partners

Eight Advisory

financial advisors

Eight Advisory

Brunswick Group

pr advisors

Brunswick Group

Lazard

financial advisors

Lazard

Weil Gotshal and Manges

legal advisors

Weil Gotshal and Manges

or

Principals

INHIBRX

target

INHIBRX

SANOFI SA

bidder

SANOFI SA

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Sanofi completed the acquisition of Inhibrx for $1.7bn.